Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong · Delayed Price · Currency is HKD 57.35
-1.65 (-2.80%)
Apr 17, 2026, 1:18 PM HKT
HKG:2315 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,379 | 980.07 | 716.91 | 533.88 | 354.56 |
Other Revenue | 0.05 | 0.38 | - | - | - |
| 1,379 | 980.45 | 716.91 | 533.88 | 354.56 | |
Revenue Growth (YoY) | 40.63% | 36.76% | 34.28% | 50.58% | 39.84% |
Cost of Revenue | 348.55 | 225.07 | 206 | 138.21 | 97.3 |
Gross Profit | 1,030 | 755.39 | 510.91 | 395.67 | 257.25 |
Selling, General & Admin | 361.71 | 279.68 | 349.09 | 313.66 | 230.15 |
Research & Development | 438.05 | 323.92 | 474.37 | 699.17 | 558.49 |
Other Operating Expenses | 7.76 | 11.1 | -21.04 | -12.56 | -12.32 |
Operating Expenses | 819.04 | 624.16 | 802.41 | 1,000 | 776.32 |
Operating Income | 211.22 | 131.22 | -291.5 | -604.6 | -519.07 |
Interest Expense | -71 | -91.68 | -99.84 | -56.14 | -39.43 |
Interest & Investment Income | 4.27 | 5.89 | 10.16 | 2.17 | 12.51 |
Earnings From Equity Investments | - | - | -10.03 | -14.77 | -0.4 |
Currency Exchange Gain (Loss) | -4.6 | 8.67 | 9.08 | 27.37 | -1.78 |
Other Non Operating Income (Expenses) | -1.08 | -0.61 | - | - | - |
EBT Excluding Unusual Items | 138.82 | 53.49 | -382.14 | -645.97 | -548.16 |
Gain (Loss) on Sale of Investments | 43.59 | -15.92 | 0.15 | 19.27 | 2.13 |
Gain (Loss) on Sale of Assets | 0.79 | 0.01 | 1.83 | 25.35 | 0.39 |
Other Unusual Items | 4.83 | 5.36 | - | - | - |
Pretax Income | 188.03 | 42.94 | -380.16 | -601.35 | -545.64 |
Income Tax Expense | 14.83 | 9.4 | 2.8 | 0.8 | - |
Earnings From Continuing Operations | 173.2 | 33.54 | -382.95 | -602.16 | -545.64 |
Minority Interest in Earnings | 0 | 0 | 0 | 0.21 | 0.07 |
Net Income | 173.2 | 33.54 | -382.95 | -601.95 | -545.58 |
Net Income to Common | 173.2 | 33.54 | -382.95 | -601.95 | -545.58 |
Net Income Growth | 416.37% | - | - | - | - |
Shares Outstanding (Basic) | 403 | 419 | 398 | 381 | 362 |
Shares Outstanding (Diluted) | 403 | 419 | 398 | 381 | 362 |
Shares Change (YoY) | -3.93% | 5.26% | 4.54% | 5.13% | 180.82% |
EPS (Basic) | 0.43 | 0.08 | -0.96 | -1.58 | -1.51 |
EPS (Diluted) | 0.43 | 0.08 | -0.96 | -1.58 | -1.51 |
EPS Growth | 437.50% | - | - | - | - |
Free Cash Flow | 282.43 | 174.12 | -203.26 | -543.54 | -564.45 |
Free Cash Flow Per Share | 0.70 | 0.41 | -0.51 | -1.43 | -1.56 |
Gross Margin | 74.72% | 77.04% | 71.27% | 74.11% | 72.56% |
Operating Margin | 15.32% | 13.38% | -40.66% | -113.25% | -146.40% |
Profit Margin | 12.56% | 3.42% | -53.42% | -112.75% | -153.88% |
Free Cash Flow Margin | 20.48% | 17.76% | -28.35% | -101.81% | -159.20% |
EBITDA | 315.84 | 240.5 | -154.78 | -465.86 | -415.47 |
EBITDA Margin | 22.91% | 24.53% | -21.59% | -87.26% | -117.18% |
D&A For EBITDA | 104.62 | 109.28 | 136.73 | 138.74 | 103.6 |
EBIT | 211.22 | 131.22 | -291.5 | -604.6 | -519.07 |
EBIT Margin | 15.32% | 13.38% | -40.66% | -113.25% | -146.40% |
Effective Tax Rate | 7.89% | 21.90% | - | - | - |
Revenue as Reported | 1,379 | 980.45 | - | - | - |
Advertising Expenses | 6.02 | 4.05 | - | - | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.